Published in Drug Saf on November 01, 1998
Dyslipidemic drugs in metabolic syndrome. Indian J Endocrinol Metab (2013) 1.39
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol (2011) 0.94
HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. Clin Biochem Rev (2004) 0.77
Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid (2012) 0.76
Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy. Invest New Drugs (2007) 0.75
Drug safety: The concept, inception and its importance in patients' health. Saudi Pharm J (2014) 0.75
The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med (1993) 4.61
Drug treatment of dyslipidemias: practical guidelines for the primary care physician. Heart Dis Stroke (1994) 2.68
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med (1967) 1.97
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther (2001) 1.65
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med (1994) 1.46
The meetabolism of amiloride hydroloride in man. Clin Pharmacol Ther (1969) 1.33
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract (2003) 1.19
Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest (1971) 1.07
Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am (1973) 1.06
L-dopa treatment failure: explanation and correction. Br Med J (1970) 0.95
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol (1994) 0.92
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med (1999) 0.89
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med (1991) 0.88
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med (1987) 0.88
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
The instability of isoniazid and acetylisoniazid in frozen plasma. Res Commun Chem Pathol Pharmacol (1976) 0.86
Toxicity of a hepatotoxic laxative preparation in tissue culture and excretion in bile in man. Clin Pharmacol Ther (1972) 0.86
Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism (1993) 0.85
Plasma levels and excretion of estrogens in urine in chronic lever disease. Gastroenterology (1975) 0.85
Drug interactions with fibric acids. Pharmacol Ther (1994) 0.85
Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther (1983) 0.83
L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem Pharmacol (1971) 0.83
Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J Am Coll Nutr (1991) 0.83
Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis (1986) 0.83
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
Quantitation of biliary excretion of drugs in man. Clin Pharmacol Ther (1982) 0.82
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Methods to assess relative reliability of diet records: minimum records for monitoring lipid and caloric intake. J Am Diet Assoc (1986) 0.81
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
Dual hepatic metabolism of cerivastatin--clarifications. Am J Cardiol (1999) 0.81
The interaction between halofenate and propranolol. Clin Pharmacol Ther (1976) 0.80
Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemic and normal subjects. Arch Intern Med (1986) 0.80
Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis (1988) 0.80
Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial. Ann Intern Med (1988) 0.80
A two-year crossover therapeutic trial with halofenate and clofibrate. Am J Med Sci (1977) 0.80
Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther (1990) 0.80
Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol (1997) 0.79
Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol. Clin Pharmacol Ther (1984) 0.79
Experimental bases for the different hepatotoxicity of erythromycin preparations in man. J Lab Clin Med (1972) 0.79
Hepatotoxicity of phenothiazines in vitro as measured by loss of aminotransferases to surrounding media. Proc Soc Exp Biol Med (1968) 0.79
A clinical pharmacologist's view of drug hepatotoxicity. Pharmacol Res Commun (1977) 0.79
Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol (1978) 0.78
The correlation of serum levels of two transaminases with tissue levels in six vertebrate species. Comp Biochem Physiol (1968) 0.78
Probucol. Curr Atheroscler Rep (2000) 0.78
Comparative clinical therapeutic trial with two hypolipidemic drugs: lofibrate and nafenopin. Clin Pharmacol Ther (1971) 0.78
Liver cell culture toxicity and surfactant potency of erythromycin derivatives. Toxicol Appl Pharmacol (1975) 0.78
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 0.78
The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man. Thromb Res (1990) 0.77
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol (1995) 0.77
Chlorpromazine uptake by isolated rat hepatocytes. Proc Soc Exp Biol Med (1979) 0.77
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. Clin Cardiol (2001) 0.76
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis (1995) 0.76
Cytotoxicity of phenothiazines on Chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med (1969) 0.76
One-year trials with halofenate, clofibrate, and placebo. Clin Pharmacol Ther (1976) 0.76
Omega-3 fatty acids in hypertriglyceridemic patients: triglycerides vs methyl esters. Am J Clin Nutr (1988) 0.76
Clinical trial design for obesity agents: a workshop report. Obes Res (1998) 0.75
Hepatocyte responses to volatile anesthetics: changes in surface scanning and enzyme leakage. Anesth Analg (1979) 0.75
The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study. Am J Cardiol (1997) 0.75
The high risk cardiovascular patient. Kans Med (1985) 0.75
Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients. Clin Pharmacol Ther (1970) 0.75
Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol. Clin Pharmacol Ther (1989) 0.75
Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease. J Ky Med Assoc (1993) 0.75
Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med (1984) 0.75
Surface activity, cellular uptake and cytotoxicity of tricyclic psychoactive drugs in vitro. Biochem Pharmacol (1979) 0.75
One hundred digitalis blood levels. A utilization review. Eur J Clin Pharmacol (1979) 0.75
Calcium and CNS symptoms. N Engl J Med (1969) 0.75
Toxicity of promazine and chlorpromazine to isolated rat hepatocytes and its modification by liposome entrapment. Pharmacology (1986) 0.75
Comparison of two scoring systems used to monitor diets in outpatient clinical trials. J Cardiovasc Risk (1995) 0.75
Ethical, medical and legal issues for the use of placebos in future lipid intervention trials. Curr Opin Lipidol (2001) 0.75
Colestipol and clofibrate in hypercholesterolemia. Clin Pharmacol Ther (1974) 0.75
Alterations of liver-cell membranes after exposure to halothane. N Engl J Med (1980) 0.75
Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. Pharmacology (1980) 0.75
AHA Conference Report on Cholesterol. Drug therapy. Circulation (1989) 0.75
Hepatotoxicity of general anesthetics on rat hepatoma cells in culture. Proc Soc Exp Biol Med (1976) 0.75
Lipid-altering drugs in development. Drugs R D (1999) 0.75
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Prog Drug Res (1994) 0.75
Relationship between surface activity and toxicity to Chang liver cultures of tricyclic antidepressants. Pharmacology (1979) 0.75
Controlled studies of the efficacy and safety of combined probucol-colestipol therapy. Am J Cardiol (1986) 0.75
The treatment of hyperlipoproteinemias. Ration Drug Ther (1979) 0.75
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority. Postgrad Med (1992) 0.75
Low-dose colestipol plus probucol for hypercholesterolemia. Am J Cardiol (1984) 0.75
A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients. Am J Med Sci (1979) 0.75
Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol (1984) 0.75
The European (EAS) and the American (NCEP) cholesterol guidelines: are they still adequate? Postgrad Med J (1989) 0.75
Prevention of toxicity to isolated hepatocytes by liposome entrapment of chenodeoxycholic acid. Toxicol Lett (1984) 0.75
Platelet function in hypercholesterolemics before and after hypolipidemic drug therapy. Haemostasis (1986) 0.75
Tumors potentiating catecholamine-induced hypertension. Life Sci I (1971) 0.75
Drug treatment of hyperlipidemia. Ration Drug Ther (1984) 0.75
Experimental investigations on the different hepatotoxic potential of erythromycin derivatives. Med Chir Dig (1976) 0.75
The correlation between serum and tissue levels of enzymes in six vertebrate species--studies on lactate dehydrogenase, phosphohexose isomerase, aldolase and malate dehydrogenase. Comp Biochem Physiol (1969) 0.75
Interaction of mestranol with taurocholate uptake by isolated rat hepatocytes. Res Commun Chem Pathol Pharmacol (1979) 0.75
Toxicity of hepatotoxic drugs on mouse liver tissue culture. Arch Int Pharmacodyn Ther (1970) 0.75
Liver cell culture toxicity of general anesthetics. Toxicol Appl Pharmacol (1976) 0.75
The effect of variable fat diets and cholesterol-lowering drugs on Antithrombin III levels in hyperlipoproteinemic and normal subjects. Thromb Res (1983) 0.75
Hepatotoxicity and surface activity of tricyclic antidepressants in vitro. Toxicol Appl Pharmacol (1979) 0.75
Changes in liver and spleen scans of patients during treatment with two hypolipidemic drugs. Radiology (1971) 0.75